Press Releases

Press Releases
Date Title and Summary View
11/03/2016 Oral presentation and six posters illustrate advancement of GlycoMimetics' pipeline Poster presentation will update clinical data from on-going AML study of GMI-1271 ROCKVILLE, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ: GLYC) today announ...
09/14/2016 Trial to test candidate for second blood cancer type among patients responding poorly to standard therapy ROCKVILLE, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ: GLYC) today announced it has dosed its first patient in a Phase 1 clinical trial of its novel E-selectin antagonis...
09/08/2016
PDF
Add to Briefcase
09/06/2016 First-in-Humans Study of Third GlycoMimetics Drug Candidate ROCKVILLE, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ: GLYC) today announced dosing of the first healthy volunteers in a new Phase 1 clinical trial evaluating its novel combined E-selectin and CXCR4 antagonist GMI-...
08/16/2016 Research shows effectiveness in stabilizing atherosclerotic plaques, reducing risk of further injury due to reduced blood flow ROCKVILLE, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ: GLYC) today announced the publication of results from a preclinical study that showed its ...
08/08/2016 ROCKVILLE, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Chief Executive Officer Rachel King will provide a company overview at Canaccord Genuity 36th Annual Growth Conference in Boston, on Thursday, August 11, 2016 2:30 p.m. ET. To access the live webcast...
08/04/2016 ROCKVILLE, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ: GLYC) today reported financial results for the second quarter and six months ended June 30, 2016. "For GlycoMimetics, the second quarter was highlighted by both financial and clinical achievements. We completed a follow-on public offer...
06/28/2016 ROCKVILLE, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ: GLYC) today announced dosing of the first patient with newly diagnosed acute myeloid leukemia (AML) in the Phase 2 portion of its ongoing Phase 1/2 study evaluating its novel E-selectin antagonist, GMI-1271, combined with chemotherapy. Earlier this mo...
06/17/2016 ROCKVILLE, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ: GLYC), a clinical stage biotechnology company focused on the discovery and development of novel glycomimetic drugs, today announced the pricing of its underwritten public offering of 3,300,000 shares of its common stock at a price to the public of ...
06/16/2016 ROCKVILLE, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ: GLYC), a clinical stage biotechnology company focused on the discovery and development of novel glycomimetic drugs, today announced that it intends to offer and sell, subject to market conditions, shares of its common stock in an underwritten public ...
FirstPrevious
2
... NextLast
Add to Briefcase = add release to Briefcase